首页 | 本学科首页   官方微博 | 高级检索  
     


Discovery of benzophosphadiazine drug candidate IDX375: A novel hepatitis C allosteric NS5B RdRp inhibitor
Authors:Jean-Laurent Paparin  Agnès Amador  Eric Badaroux  Stéphanie Bot  Catherine Caillet  Thierry Convard  Daniel Da Costa  David Dukhan  Ludovic Griffe  Jean-François Griffon  Massimiliano LaColla  Frédéric Leroy  Michel Liuzzi  Anna Giulia Loi  Joe McCarville  Valeria Mascia  Julien Milhau  Loredana Onidi  Cyril B. Dousson
Affiliation:1. Idenix SARL, an MSD Company, Medicinal Chemistry Laboratory, Cap Gamma, 1682 rue de la Valsière, BP50001, 34189 Montpellier Cedex 4, France;2. Former Idenix employee
Abstract:
Hepatitis C virus (HCV) NS5B RNA-dependent RNA polymerase (RdRp) plays a central role in virus replication. NS5B has no functional equivalent in mammalian cells, and as a consequence is an attractive target for selective inhibition. This paper describes the discovery of a novel family of HCV NS5B non-nucleoside inhibitors inspired by the bioisosterism between sulfonamide and phosphonamide. Systematic structural optimization in this new series led to the identification of IDX375, a potent non-nucleoside inhibitor that is selective for genotypes 1a and 1b. The structure and binding domain of IDX375 were confirmed by X-ray co-crystalisation study.
Keywords:Hepatitis C virus  Direct-acting antivirals  NS5B non-nucleoside inhibitors  Allosteric inhibitors  Phosphadiazines  Phophorylated bioisosteres  Thiadiazine bioisosteres  IDX375
本文献已被 ScienceDirect 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号